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Background: The purpose of this study was to quantify right (RV) and left (LV) ventricular function, pulmonary
artery flow (QP), tricuspid valve regurgitation velocity (TRV), and aorta flow (QS) from a single 4D flow cardiovascular
magnetic resonance (CMR) (time-resolved three-directionally motion encoded CMR) sequence in a canine model of
acute thromboembolic pulmonary hypertension (PH).
Methods: Acute PH was induced in six female beagles by microbead injection into the right atrium. Pulmonary
arterial (PAP) and pulmonary capillary wedge (PCWP) pressures and cardiac output (CO) were measured by right
heart catheterization (RHC) at baseline and following induction of acute PH. Pulmonary vascular resistance (PVRRHC)
was calculated from RHC values of PAP, PCWP and CO (PVRRHC = (PAP-PCWP)/CO). Cardiac magnetic resonance
(CMR) was performed on a 3 T scanner at baseline and following induction of acute PH. RV and LV end-diastolic
(EDV) and end-systolic (ESV) volumes were determined from both CINE balanced steady-state free precession
(bSSFP) and 4D flow CMR magnitude images. QP, TRV, and QS were determined from manually placed cutplanes in
the 4D flow CMR flow-sensitive images in the main (MPA), right (RPA), and left (LPA) pulmonary arteries, the
tricuspid valve (TRV), and aorta respectively. MPA, RPA, and LPA flow was also measured using two-dimensional
flow-sensitive (2D flow) CMR.
Results: Biases between 4D flow CMR and bSSFP were 0.8 mL and 1.6 mL for RV EDV and RV ESV, respectively, and
0.8 mL and 4 mL for LV EDV and LV ESV, respectively. Flow in the MPA, RPA, and LPA did not change after
induction of acute PAH (p = 0.42-0.81). MPA, RPA, and LPA flow determined with 4D flow CMR was significantly
lower than with 2D flow (p < 0.05). The correlation between QP/TRV and PVRRHC was 0.95. The average QP/QS was
0.96 ± 0.11.
Conclusions: Using both magnitude and flow-sensitive data from a single 4D flow CMR acquisition permits
simultaneous quantification of cardiac function and cardiopulmonary hemodynamic parameters important in the
assessment of PH.
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Pulmonary hypertension (PH) is an ultimately fatal disease
characterized by an abnormal increase in the mean
pulmonary artery pressure (mPAP) that ultimately leads
to right ventricular (RV) failure [1]. The initial evaluation
of patients with suspected PH includes non-invasive im-
aging with echocardiography because of its ability to non-
invasively estimate pulmonary artery pressures, pulmonary
vascular resistance (PVR) and cardiac function [2]. De-
pending upon the results of the initial assessment with
echocardiography, further imaging work-up to identify the
underlying cause and determine appropriate management
of PH may include ventilation/perfusion scintigraphy
in patients with known or suspected chronic thrombo-
embolic PH, computed tomography to assess for diffuse
lung disease, and invasive right heart catheterization
(RHC) [3] to confirm the diagnosis. Currently, RHC is
considered the reference standard for assessing PH
patients and providing definite diagnosis, because the
categorization of the type of PH is based on the observed
pulmonary artery pressures (mPAP > 25 mmHg), pulmon-
ary capillary wedge pressure (PCWP < than 15 mmHg)
and pulmonary vascular resistance (PVR > 3WU) [4].
Cardiovascular magnetic resonance (CMR) is increas-
ingly being used to monitor pulmonary hemodynamics
and cardiac function in patients with PH. Flow-sensitive
CMR sequences can be used to measure pulmonary ar-
tery flow (QP) flow and TRV, and thereby estimate PVR
(PVRRHC ∝ TRV/Qp) using a method analogous to that
used by Abbas et al. for echocardiography [5]. Using this
model, TRV is used as a surrogate of peak systolic pul-
monary arterial pressure and reflects the trans-tricuspid
gradient. With respect to cardiac size and function, CMR
is considered the gold standard for quantification of left
[6-8] and right [9-11] ventricular size and function with
time-resolved “CINE” balanced steady-state free preces-
sion (bSSFP) imaging due to its high reproducibility.
In this study we have investigated an alternative CMR
approach to assess flow and ventricular function using a
single 4D flow MR sequence that uses a radially under-
sampled, time-resolved, 3-dimensional, 3-directionally
velocity-encoded imaging scheme [12]. Ventricular size
and function were measured using the time-resolved
magnitude images and compared with values obtained
using standard CINE bSSFP and two-dimensional flow-
sensitive (2D flow) imaging. Tricuspid valve, pulmonary
artery and aorta flow was quantified using the time-
resolved phase images and compared with ventricular
stroke volumes obtained using volumetric methods. In
addition, the ratio of TRV/QP was correlated to PVRRHC
to determine if this method could also be used to esti-
mate PVR non-invasively. A benefit of using the same
sequence for measuring cardiac chamber volumes and
flow includes an overall shortened examination acquisitiontime (particularly in cases where numerous flow measure-
ments are required). In addition, a free-breathing acquisi-
tion is beneficial in patients who have difficulty with the
numerous breath holds required using standard cardiac
MR sequences. Although not explored in this study, 4D
flow MR has been shown to be of use in assessing add-
itional hemodynamic characteristics of normal and abnor-
mal flow in a variety of cardiovascular diseases [13].
Methods
Acute canine thromboembolic pulmonary hypertension
model
All studies were approved by the institutional local ani-
mal care and use committee (RARC). Acute PAH was
induced by injection of micro-beads (150–500 μm) in
the right atrium and ventricle in six adult female beagles
(8.3 ± 2.4 kg). Dogs were anesthetized with propofol
(10 mg/kg body weight), intubated, and maintained
under anesthesia with isoflurane (1 to 3%) with 100% oxy-
gen. During anesthesia, ventilation was adjusted to keep
end-tidal CO2 within normal limits (30–50 mmHg). A
femoral arterial catheter was inserted and systemic arterial
pressure (SAP) and arterial blood gases were monitored.
The femoral and external jugular veins were catheterized
for RHC access, delivery of emboli, delivery of contrast for
angiography and blood sampling.
While maintaining the dog under anesthesia, CMR and
RHC were repeated twice, the first prior to induction of
PH to obtain baseline data, and the second repeating all
acquisitions after successful induction of thromboembolic
PH (confirmed by > twofold increase in baseline mPAP).
The dogs were euthanized according to the RARC proto-
col after the post-embolization CMR study.
Right heart catheterization
After induction of anesthesia, dogs were granted a resting
period of approximately 30 minutes to ensure adaptation
of the circulation to anesthesia. Baseline pulmonary arter-
ial pressure (PAP), pulmonary capillary wedge pressure
(PCWP) and right ventricular cardiac output (QP) were
measured. Measurements were made using a 7.5-French,
fluid-filled catheter connected to an analog pressure re-
corder. PVR [in Woods units (WU)] was calculated using
the formula, analogous to Ohm’s law for electrical circuits:
PVRRHC =ΔP/QP, where ΔP is the trans-pulmonary pres-
sure gradient (ΔP =mPAP - PCWP) [14] and QP is the
flow in the pulmonary artery measured by thermodilution.
Magnetic resonance imaging
CMR measurements were performed prior to and follow-
ing induction of PH resulting in a total of 12 measure-
ments on a 3.0 T clinical systems (MR750, GE Healthcare,
Waukesha, WI). Contiguous axial CINE bSSFP slices were
obtained covering the entire heart. Parameters for CINE
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224 × 192 acquisition matrix, 7 mm slice thickness, 0 mm
gap, ±125 kHz bandwidth, 45° flip angle, TR/TE = 3.1/
1.1 ms (fractional echo readout), and a prospectively
gated, k-space segmented acquisition (12 views per seg-
ment), for an acquired temporal resolution of 37 ms. 20
temporally interpolated time frames were reconstructed at
each slice location. Between 13 and 16 slices were ac-
quired depending on subject anatomy. Each slice was
acquired within an 8 to 10 second time interval of sus-
pended ventilation.
2D and 4D flow CMR were performed following the
administration of 0.1 mmol/kg of Gd-based intravenous
contrast (gadobenate dimeglumine, Bracco Diagnostics,
Inc., Princeton, NJ). A standard 2D flow CMR sequence
was used to assess flow through the main, right, and left
pulmonary arteries (MPA, RPA and LPA, respectively).
Parameters for 2D flow imaging were: 160-220 × 160-
176 mm field of view, 256 × 128 acquisition matrix,
5 mm slice thickness, TR/TE = 5.53-5.93/3.17-3.44 ms,
and a prospectively gated, k-space segmented acquisi-
tion. Temporal resolution was 22.11-35.44 ms and data
were interpolated to 20 reconstructed time frames for
each location. 2D flow CMR acquisitions were per-
formed during a breath-hold at end-expiration.
4D flow CMR was performed using a previously de-
scribed 3D radial sequence [15]. Parameters were: imaging
volume = 320 × 320 × 220 mm, readout length = 256 sam-
ples, TR/TE = 6.7/2.4 ms, flip angle 10-20°, spatial reso-
lution = 1.3 mm isotropic. Retrospective ECG-gating was
used. Respiratory triggering with bellows allowed for
breathing compensation with an acceptance rate of 50%,
resulting in a scan duration of 10–12 min during free
breathing. Data were retrospectively sorted into 20 time
frames according to their position in the cardiac cycle.
Subsequently, image reconstruction was performed utiliz-
ing a compressed sensing reconstruction and a temporal
filter for view sharing [16]. To minimize the number of
slices needing manual segmentation for measuring ven-
tricular volumes, three contiguous slices were averaged. In
addition, time-resolved 4D flow CMR magnitude images
were reformatted into the left-ventricular short-axis (SA)
orientation using home-built MatLab software, for a sec-
ond, more convenient LV segmentation.
CMR analysis
RV and LV function
RV and LV end-diastolic (EDV) and end-systolic (ESV)
volumes were determined from manually segmented
contours of end-diastolic and end-systolic bSSFP and 4D
flow CMR images (Figure 1), respectively. Segmentation
of bSSFP images was accomplished using ReportCard
(GE Healthcare, Waukesha, WI). Segmentation of 4D
flow CMR images was conducted using Osirix (Pixmeo,Geneva, Switzerland). Stroke volume (SV = EDV-ESV)
and ejection fraction (EF = SV/EDV) were also determined
for both bSSFP and 4D flow CMR.
Flow quantification
Analysis of the 2D flow CMR data was performed with
CV flow (Medis, Leiden, the Netherlands). The MPA,
RPA, and LPA were manually segmented at each phase
of the cardiac cycle. Net flow per heart beat was re-
corded for each location. Average velocity was recorded
for the MPA only. PVR was estimated from 2D flow and
2D CINE bSSFP data using the following equation
PVRCMR (WU) = 19.38 – [4.62 · lnPA average velocity] –
[0.08 · RVEF] [17].
Quantitative flow analysis of the 4D flow CMR data-
sets was performed with a previously described Matlab-
based home built software (The MathWorks, Natick,
MA, USA) [18]. Two-dimensional cutplanes were manu-
ally placed perpendicular to the direction of the flow in
the tricuspid valve, MPA, RPA, LPA (Figure 2) and aorta
(Figure 3) using Ensight (CEI, Apex, NC, USA). Specific-
ally, the tricuspid valve plane was generated using flow
streamlines, which allowed for localization of the peak
tricuspid regurgitation velocity with no need for annular
motion compensation. From these analyses, we recorded
(a) the peak tricuspid valve regurgitation velocity (TRV)
for the generated two-dimensional tricuspid valve cut-
plane; (b) net flow, time-to-peak flow, and time-to-peak
acceleration in the MPA, RPA, and LPA; and (c) net flow
in the aorta. To assess the internal consistency of the
flow measurements, we determined the relative flow
through the RPA and LPA, as a percentage of MPA flow,
and the ratio of pulmonary (QP) to aorta (QS) flow.
Statistical analysis
Values are reported as mean ± standard deviation. Differ-
ences between flow (2D and 4D) and CINE bSSFP and
between the two flow techniques were assessed using
Bland-Altman analysis. Linear regression analysis was
used to determine the Pearson correlation coefficients
between TRV/QP and PVRRHC and mPAP. A linear re-
gression equation was derived to calculate PVR4Dflow
from the imaging parameters. Bland-Altman analysis was
used to assess the differences between the PVRRHC and
PVR4Dflow and PVRCMR. Values obtained prior to and
following induction of PH were compared used a paired
Student’s t-test. P-values less than 0.05 were considered
statistically significant.
Results
RV and LV function
Mean values for RV and LV volumes using CINE bSSFP
and 4D flow CMR are summarized in Table 1. Differences
in RV EDV, ESV, and SV were not significant (P > 0.05).
Figure 1 Surface-shaded angiographic image (top left) from 4D flow MRI dataset revealing right- (blue) and left- (red) sided circulations.
Right (RV) and left (LV) ventricular volumes were calculated from bSSFP (top right) and 4D flow MRI magnitude (bottom left) images in the axial
orientation (dashed line). In addition, the time-resolved 4D flow MRI magnitude dataset was reformatted into the LV short-axis orientation (bottom right
and indicated by solid line in top left).
Figure 2 Surface-shaded angiographic image from 4D flow MRI
dataset indicating locations of flow quantification in the right-
sided circulation. Flow analysis was performed at the level of the
tricuspid valve (TV), main pulmonary artery (MPA), right pulmonary
artery (RPA), and left pulmonary artery (LPA). The ratio of the peak
tricpuspid regurgitation velocity (TRV) to flow through the MPA (QP)
was correlated to pulmonary vascular resistance at right heart
catheterization (PVRRHC).
Figure 3 Surface-shaded angiographic image from 4D flow MRI
dataset indicating location of flow analysis in the ascending
aorta.
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Table 1 Summary of right (RV) and left (LV) ventricular
volumes measured from standard CINE balanced
steady-state free precession (bSSFP) and 4D flow CMR
magnitude images (PC-VIPR)
CINE bSSFP 4D flow CMR
RV Axial Axial
EDV (mL) 34.5 ± 8.1 35.3 ± 10.2
ESV (mL) 19.6 ± 5.8 21.2 ± 6.8
SV (mL) 14.8 ± 3.1 14.1 ± 4.1
EF 0.44 ± 0.07 0.40 ± 0.06
CO (L/min) 1189 ± 286 1145 ± 417
LV Axial Axial Short-axis
EDV (mL) 22.3 ± 5.4 23.8 ± 6.5 23.0 ± 6.2
ESV (mL) 9.1 ± 3.6 12.5 ± 4.21 13.1 ± 3.81
SV (mL) 13.1 ± 3.6 11.3 ± 3.01 9.9 ± 3.41,2
EF 0.59 ± 0.11 0.48 ± 0.071 0.43 ± 0.091,2
CO (L/min) 1059 ± 358 907 ± 2951 798 ± 3221,2
LV volumes were determined from both axial and short-axis (SA) images. Data
from pre- and post-embolization CMR studies are combined.
1P < 0.05 with respect to CINE bSSFP. 2P < 0.05 with respect to axial 4D flow
CMR. Abbreviations – EDV End-diastolic volume, ESV End-systolic volume,
SV Stroke volume, EF Ejection fraction, CO Cardiac output.
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structions did not significantly differ from that measured
using axial CINE bSSFP (P > 0.05). LV ESV and SV were
significantly larger with 4D flow CMR than CINE bSSFP
using both axial and short-axis reconstructions (P < 0.05).
LV EDV and SV were smaller (P = 0.02 and 0.001, re-
spectively) and LV ESV was larger (P = 0.10) when




Results of the flow analysis in the MPA, RPA and LPA
are summarized in Tables 2 and 3. One pre- and one
post-embolization 4D flow datasets were excluded due
to inadequate imaging quality. Flows were significantly
higher with 2D flow than with 4D flow. Relative flow
through the RPA and LPA was 61% and 39%, respect-
ively, with 4D flow and 59% and 41%, respectively, withTable 2 Summary of pulmonary artery flow quantification pre
techniques
2D Flow
MPA RPA LPA RPA
Pre + Post 18.9 ± 4.51,2 10.7 ± 3.22 7.7 ± 3.82 18.4
Pre 19.25 ± 4.51,2 11.1 ± 2.92 8.0 ± 2.9 19.1
Post 18.6 ± 5.01,2 10.4 ± 3.82 7.3 ± 4.8 17.7
All values are mean flow per heart beat ± standard deviation (mL). 1 – P < 0.05 for MPA
compared to 4D flow. Differences in flow pre- and post-embolization were not signific
artery, LPA Left pulmonary artery.2D flow. The average flow through the RPA and LPA
combined (12.6 ± 3.5 mL/cycle with 4D flow and 18.4 ±
6.4 mL/cycle with 2D flow) was not significantly differ-
ent from the flow measured through the MPA (12.0 ±
3.9 mL/cycle with 4D flow, P = 0.96, and 18.9 ± 3.1 mL/
cycle with 2D flow, P = 0.70).
Comparing flow data pre- and post-embolization, the
differences in MPA, RPA, and LPA flows were not sig-
nificant. Although there was a trend toward faster
time-to-peak flow and time-to-peak acceleration values
post-embolization in the pulmonary arteries, these changes
were not significant (Table 3). Time-to-peak acceleration
was shorter post-embolization than pre-embolization, al-
though this difference was not significant (Table 3).
Aorta
The average aortic flow (QS) using 4D flow CMR was
11.6 ± 4.0 mL/cycle (P = 0.06 with bSSFP and 0.08 with
4D flow CMR volumetry). The mean difference between
QS with 4D flow CMR and LV SV calculated from 4D
flow CMR was −0.7 mL. The difference between QS and
MPA flow (QP) calculated from 4D flow CMR phase-
sensitive data was not statistically significant (P = 0.30).
Furthermore, the average QP/QS was 0.96 ± 0.11 (range:
0.87-1.21). Differences in aortic flow pre- and post-
embolization, 12.0 ± 3.8 mL/cycle and 11.1 ± 4.4 mL/
cycle, respectively, did not reach statistical significance
(P = 0.81).
PVR
Tricuspid regurgitation was detected in all canines pre-
and post-embolization, enabling calculation of PVRCMR in
all cases. PVRRHC values pre- and post-embolization were
2.4 ± 0.9 WU and 9.8 ± 5.7 WU, respectively (Figure 4).
The Pearson correlation coefficient between TRV/QP
and PVRRHC was 0.95 for combined pre- and post-
embolization data (Figure 5). When analysing the data
pre- and post-embolization separately, the correlation be-
tween TRV/QP and PVRRHC was higher post-embolization
(R = 0.99) than pre-embolization (R = 0.26). The Pearson
correlation coefficient between TRV/QP and mPAP was
0.65. The equation for calculating PVR4Dflow using the
combined data was PVR4Dflow (WU) = 0.16(TRV/QP) –- and post-embolization using 2D and 4D flow
4D Flow
+ LPA MPA RPA LPA RPA + LPA
± 6.42 12.0 ± 3.91 7.6 ± 2.2 4.8 ± 2.1 12.6 ± 3.51
± 5.42 12.2 ± 3.31 7.4 ± 2.3 4.8 ± 2.7 12.5 ± 4.0
± 7.72 11.8 ± 4.6 7.8 ± 2.3 4.9 ± 1.3 12.7 ± 3.5
flow compared to Cine 2D bSSFP right ventricular stroke volume. 2 – P < 0.05
ant (P≥ 0.05). Abbreviations – MPA Main pulmonary artery, RPA Right pulmonary
Table 3 Summary of time-to-peak flow and acceleration in main, right and left pulmonary arteries (MPA, RPA, and
LPA, respectively) measured from 4D flow data
TTP flow (ms) TTP acceleration (ms)
MPA RPA LPA MPA RPA LPA
Pre + Post 279 ± 170 298 ± 149 305 ± 145 219 ± 161 238 ± 150 223 ± 141
Pre 339 ± 176 337 ± 161 351 ± 136 261 ± 162 270 ± 159 234 ± 149
Post 230 ± 163 259 ± 144 248 ± 149 184 ± 167 206 ± 152 210 ± 147
Differences in TTP flow and acceleration pre- and post-embolization were not significant (P ≥ 0.05).
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embolization were 3.3 ± 1.8 WU (P = 0.35 for PVR4Dflow
vs. PVRRHC) and 9.0 ± 6.2 WU (p = 0.15 for PVR4Dflow vs.
PVRRHC), respectively (Figure 4). In one case, PVR4Dflow
was lower post embolization. The mean difference be-
tween PVR4Dflow and PVRRHC was 0 (WU) with positive
and negative levels of agreement of 3.52 and −3.52 (WU),
respectively (Figure 6).
Using 2D flow and 2D CINE bSSFP, PVRCMR was 5.0 ±
1.6 (WU) pre-embolization (P = 0.051 with PVRRHC
and 0.21 with PVR4Dflow) and 7.5 ± 1.3 (WU) post-
embolization (P = 0.38 with PVRRHC and 0.66 with
PVR4Dflow) (Figure 4). PVRCMR increased post-embolization
in all cases. The Pearson correlation coefficients betweenFigure 4 Scatter-plot of PVRRHC, PVR4Dflow and PVRMRI pre- and
post-embolization. PVRRHC and PVRMRI increased post-embolization in
all cases. In one case, PVR4Dflow was lower post-embolization than pre-
embolization, presumably due to lack of an increase in tricuspid regur-
gitation (TR) jet velocity or incorrect selection of the peak TR velocity.PVRCMR and PVRRHC was 0.78 for combined pre- and
post-embolization data, 0.03 for pre-embolization data
and 0.91 for post-embolization data.. The mean difference
between PVRCMR and PVRRHC was 0.18 (WU) with posi-
tive and negative levels of agreement of 8.4 and −8.0
(WU), respectively.
Discussion
In this study we demonstrated the feasibility of measuring
RV and LV function and pulmonary vascular resistance
from a single, free breathing 4D flow CMR sequence. RV
and LV volumes were measured using the time-resolved
magnitude data from the same 4D flow CMR acquisition.
Using the three-directional velocity information, we found
a strong correlation between the ratio of the peak tricus-
pid regurgitation velocity to the flow through the pulmon-
ary arteries (TRV/QP) and PVR determined at RHC, using
an approach that is analogous to that used for echocardi-
ography [5].
RV and LV function
Cardiac magnetic resonance using breath-hold CINE
balanced steady-state free precession imaging (bSSFP) is
considered the gold standard for quantification of ven-
tricular size and function [6-11]. However, in patients
with PH, dyspnea can be severe, and the multiple breath-
holds required to scan the entire heart can be difficult, orFigure 5 Derivation of PVRMRI equation from the linear regression
between TRV/ QP and PVRRHC (PVRMRI = 0.16(TRV/ QP) – 7.25).
Figure 6 Bland-Altman plot for comparison of PVR calculated
from RHC measurements and estimated from 4D Flow MRI data.
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to use free-breathing acquisition methods with respiratory
navigation or triggering to coordinate data acquisition
with the respiration, as was done here with the 4D flow
MR approach. Using a volumetric (3D) approach to asses-
sing cardiac function would also be beneficial in that it
would enable quantification of RV and left ventricular
(LV) volumes simultaneously, which is important because
the most common cause of pulmonary hypertension is left
heart disease [19]. Quantification of LV and RV function
using time-resolved 3D acquisitions has previously been
demonstrated using both free-breathing and breath-hold
bSSFP techniques [20,21]. Although free-breathing ap-
proaches to cardiac function analysis are longer than sin-
gle breath-hold acquisitions, in our clinical experience,
patients with PH frequently have difficulty holding their
breath for even more than 10 seconds. Future studies in
PH patients comparing these two approaches to whole-
heart functional analysis are warranted. LV ESV was larger,
and therefore LV SV was smaller, with time-resolved mag-
nitude reconstructions from the 4D flow CMR dataset
than with the standard 2D bSSFP acquisition. This may be
partially related to the higher spatial resolution with the
4D flow CMR data, resulting in improved delineation of
the blood-myocardial interface, which is frequently a chal-
lenge when using standard 2D bSSFP. The results from
our study are encouraging in that the bias we observed
using a 3D radially undersampled approach was of the
same magnitude as previously published studies.
Estimation of PVR
Currently, Doppler echocardiography is used clinically in
patients with PH to estimate PVR from the ratio of the
TRV to the velocity time integral in the right ventricular
outflow tract (VTIRVOT), which is a surrogate of the flow
through the pulmonary artery (QP) [5]. Abbas et al. re-
ported a strong linear correlation between TRV/VTIRVOTand PVRRHC and proposed calculating PVR from the fol-
lowing equation: PVR = 10 × TRV/VTIRVOT in Woods
units (WU). However, a potential important limitation of
this approach is that Doppler ultrasound does not meas-
ure flow directly, but rather the velocity time integral
which does not take into account the area of the vessel of
interest. Furthermore, echocardiography-based methods
of assessing PVR can be limited by body habitus or
other anatomical factors obstructing the acoustic win-
dow. In contrast, CMR-based flow sequences can be
used to measure flow, in addition to velocity, without
the limitations of echocardiography. As a result, other
investigators have used CMR to estimate PVR, generat-
ing similar models based on cardiac function and pul-
monary artery flow. Garcia-Alvarez et al. [17] derived
an equation for calculating PVR using the average MPA
velocity and the RVEF. This model was derived in a co-
hort of human PH subjects [17] and subsequently vali-
dated in a second cohort and in a more recent canine
model of acute and chronic thromboembolic PH [22].
Swift et al. [23] created a model to estimate PVR based
on left atrial size (as an estimate of PCWP) and a linear
regression equation for calculating mPAP from the in-
terventricular septal angle and ventricular mass index.
As with our study, limits of agreement for determining
PVR using these models were also fairly wide, −6.0 to
4.9 WU (Garcia-Alvarez [17]) and −5.1 to 4.6 WU (Swift
[23]). Although the bias we observed for PVRCMR
method using 2D flow and 2D CINE bSSFP was minimal
(0.18 WU), the limits of agreement were fairly wide, wider
than what we observed using the TRV/VTIRVOT method
and wider than what was reported by Garcia-Alvarez et al.
Flow quantification with 4D flow
4D flow CMR has been used previously to evaluate PH.
Qualitatively assessing flow patterns in the MPA, Reiter
et al. [24] reported that in patients with pulmonary arter-
ial hypertension abnormal separation between the bound-
ary layer next to the wall of the MPA resulted in abnormal
vortex development in the MPA. In addition, they re-
ported delayed acceleration times in the MPA [24]. These
hemodynamic phenomena should influence PA-RV inter-
actions by changing both PVR and RV function. Interest-
ingly, we did not detect a significant difference in time-to-
peak acceleration. In fact, we found an earlier time to peak
flow after pulmonary artery embolization and induction of
PH. The different observations between this study and
that of the Reiter group are presumably related to differ-
ences in the etiology of PH, acute in the current study and
chronic in the study by Reiter et al. [24].
A benefit of using 4D flow CMR to quantify blood
flow is that quantification can be performed of any
vessel within the imaging volume a posteriori. In cases
where flow quantification is performed in numerous
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celerated 4D flow CMR methods than using standard
2D flow CMR techniques. The stroke volumes mea-
sured with the 4D flow CMR flow data were slightly
lower than the stroke volumes determined using Cine
bSSFP. MPA flow volumes with 4D flow CMR were
substantially lower than values observed with 2D flow
CMR. Frydrychowicz et al. [15] also reported under-
estimation of Qp and Qs using the same 4D flow CMR
study as that used in the current study. Some of these
differences may be related to differences in temporal
resolution and differences in flow during free breathing
(4D flow) and end-expiration (2D flow).
Limitations of the current study include the fact that the
reference standard used for LV volumes were axial CINE
bSSFP images. Although the LV short-axis orientation is
typically used to calculate LV volumes, Fratz et al. recently
reported that axial images were more reproducible than
short-axis images for calculating LV volumes in patients
with repaired tetralogy of Fallot [25]. Future studies com-
paring short-axis reconstructed 4D flow CMR data to
short-axis 2D CINE bSSFP will have to be conducted to
confirm the small bias observed in this study.
Other limitations of this study include (a) a small sample
size without a cohort to validate the model, (b) the estima-
tion of the trans-pulmonary pressure gradient assumes
that the modified Bernoulli equation is valid and requires
the presence of tricuspid valve regurgitant jet, and (c) the
fact that the equation for calculating PVR is based on
RHC data obtained during acute embolic PH, which will
most likely not be applicable to chronic PAH. In acute
pulmonary embolism, right atrial pressures are elevated,
reducing the RA-RV pressure gradient and, therefore, low-
ering the peak TRV. Although acute pulmonary embolism
is the most common cause of acute PH [26], it is not clear
from this study if these results would be transferable
to acute pulmonary thromboembolism in humans or
to other etiologies of PH. Subsequent studies will have to
be conducted to assess the relationship between TRV/QP
in other causes of PH, including in humans.Conclusions
In conclusion, this study demonstrates the feasibility of
comprehensively estimating pulmonary vascular resist-
ance, assessing ventricular function and pulmonary ar-
tery hemodynamics in a canine model of acute embolic
PH using 4D flow CMR. Although not explored in this
study, another potential benefit of using 4D flow CMR
to assess PH is the derivation of additional hemodynamic
parameters such as wall shear stress [16,18,27,28] and pulse
wave velocities [29,30], which could provide further insights
into pulmonary artery remodeling and interactions between
pulmonary arterial stiffening and RV dysfunction.Competing interests
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